Prophylaxis of migraine headache.
作者信息
Pringsheim Tamara, Davenport W Jeptha, Becker Werner J
机构信息
Department of Clinical Neurosciences, University of Calgary, Calgary Headache Assessment and Management Program, Foothills Medical Centre, 1403-29th St. NW, Calgary AB T2N 2T9.
出版信息
CMAJ. 2010 Apr 20;182(7):E269-76. doi: 10.1503/cmaj.081657. Epub 2010 Feb 16.
Abstract
摘要
相似文献
1
Prophylaxis of migraine headache.
CMAJ. 2010 Apr 20;182(7):E269-76. doi: 10.1503/cmaj.081657. Epub 2010 Feb 16.
2
Pharmacological prevention of migraine.
BMJ. 2011 Feb 18;342:d583. doi: 10.1136/bmj.d583.
3
Botulinum toxin for chronic migraine.
Med Lett Drugs Ther. 2011 Jan 24;53(1356):7-8.
4
OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem.
Headache. 2013 May;53(5):824-6. doi: 10.1111/head.12065. Epub 2013 Mar 6.
5
Onabotulinumtoxin [corrected] A (Botox).
Headache. 2014 Apr;54(4):787-8. doi: 10.1111/head.12342.
6
Botulinum toxin type A for the treatment of migraine.
Expert Opin Pharmacother. 2006 Jun;7(8):1085-95. doi: 10.1517/14656566.7.8.1085.
7
Can Botulinum Toxin Help Prevent Migraine in Adults?: A Cochrane Review Summary With Commentary.
Am J Phys Med Rehabil. 2019 Mar;98(3):245-246. doi: 10.1097/PHM.0000000000001131.
8
[Chronic and Refractory Migraine: How to Diagnose and Treat].
Acta Med Port. 2020 Nov 2;33(11):753-760. doi: 10.20344/amp.12004.
9
Flunarizine vs. pizotifen in migraine prophylaxis: a review of comparative studies.
Cephalalgia. 1988;8 Suppl 8:27-30. doi: 10.1177/03331024880080S806.
10
Re: "Botulinum toxin type A as a migraine preventive treatment" (Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group. Headache. 2000;40:445-450).
Headache. 2001 Jun;41(6):606. doi: 10.1046/j.1526-4610.2001.041006606.x.
引用本文的文献
1
Efficacy of Desvenlafaxine in Reducing Migraine Frequency and Severity: A Retrospective Study.
J Clin Med. 2024 Aug 30;13(17):5156. doi: 10.3390/jcm13175156.
2
Comparison of the efficacy of propranolol versus amitriptyline as monotherapy for prophylaxis of migraine.
J Family Med Prim Care. 2024 Feb;13(2):699-703. doi: 10.4103/jfmpc.jfmpc_927_23. Epub 2024 Mar 6.
3
Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics.
Front Mol Neurosci. 2024 Feb 28;17:1355281. doi: 10.3389/fnmol.2024.1355281. eCollection 2024.
4
ACE inhibitors and their interaction with systems and molecules involved in metabolism.
Heliyon. 2024 Jan 14;10(2):e24655. doi: 10.1016/j.heliyon.2024.e24655. eCollection 2024 Jan 30.
5
The sense of stopping migraine prophylaxis.
J Headache Pain. 2023 Feb 16;24(1):9. doi: 10.1186/s10194-023-01539-8.
6
Beneficial Extracardiac Effects of Cardiovascular Medications.
Curr Cardiol Rev. 2022;18(2):e151021197270. doi: 10.2174/1573403X17666211015145132.
7
Schizophrenia, bipolar disorder, or intracranial aneurysm? A case report.
Brain Behav. 2021 Aug;11(8):e2245. doi: 10.1002/brb3.2245. Epub 2021 Jul 21.
8
Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial.
J Pharm Health Care Sci. 2021 Apr 1;7(1):12. doi: 10.1186/s40780-021-00198-8.
9
The Use of Pharmacological Preventive Therapy for Migraine With Weight Gain Potential Amid Coronavirus Disease 2019 Pandemic.
Headache. 2020 Oct;60(9):2085-2086. doi: 10.1111/head.13945.
10
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Curr Pain Headache Rep. 2019 Sep 12;23(11):85. doi: 10.1007/s11916-019-0823-8.
本文引用的文献
1
Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation.
Phytomedicine. 1996 Nov;3(3):225-30. doi: 10.1016/S0944-7113(96)80057-2.
2
Tracing transformation: chronic migraine classification, progression, and epidemiology.
Neurology. 2009 Feb 3;72(5 Suppl):S3-7. doi: 10.1212/WNL.0b013e3181974b19.
3
Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2007 Dec;6(12):1054-62. doi: 10.1016/S1474-4422(07)70272-7. Epub 2007 Nov 7.
4
A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
Pain Med. 2007 Sep;8(6):478-85. doi: 10.1111/j.1526-4637.2006.00168.x.
5
Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
Aviat Space Environ Med. 2007 May;78(5 Suppl):B113-8.
6
Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Headache. 2007 Apr;47(4):486-99. doi: 10.1111/j.1526-4610.2006.00624.x.
7
Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Cephalalgia. 2007 Jul;27(7):814-23. doi: 10.1111/j.1468-2982.2007.01326.x. Epub 2007 Apr 18.
8
A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
Cephalalgia. 2007 Jun;27(6):492-503. doi: 10.1111/j.1468-2982.2007.01315.x. Epub 2007 Apr 11.
9
Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).
Headache. 2007 Mar;47(3):402-12. doi: 10.1111/j.1526-4610.2006.00599.x.
10
Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache.
Headache. 2007 Jan;47(1):13-21. doi: 10.1111/j.1526-4610.2007.00648.x.
Zotero 插件